However, the potential of the GHRH antagonist MIA-602 in addressing the resistance of acute promyelocytic leukemia (APL), as well as its ability to produce synergistic effects in acute myeloid leukemia (AML), have not yet been studied. This evidence concerns the gene GHRH and acute myeloid leukemia.